Drug Topics

APRIL 7, 2023

Dupilumab monotherapy plus concomitant topical corticosteroids can improve signs, symptoms, and patient health-related quality of life.

163

163

Fierce Healthcare

APRIL 3, 2024

This week on "Podnosis," we are exploring a topic that hits close to home for many: the struggles faced by LGBTQ+ patients, particularly trans men, when seeking healthcare services. | This week on "Podnosis," we are exploring a topic that hits close to home for many: the struggles faced by LGBTQ+ patients, particularly trans men, (..)

63

63

Drug Topics

OCTOBER 27, 2022

Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.

201

201

Fierce Pharma

JANUARY 24, 2024

It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgoci | It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgocitinib to treat atopic dermatitis.

86

86

Drug Topics

AUGUST 31, 2022

Drug Topics® is joined by Joseph Mann, MSN, FNP-C, to discuss pharmacy’s fast-expanding role in COVID care, variant BA.5’s 5’s diagnostic impact, and the benefits of different tests available — including how technology behind a smartphone-integrated home test creates a fluid experience for patients.

187

187

PharmaVoice

SEPTEMBER 22, 2023

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

FDA 122

FDA 122

Fierce Healthcare

MARCH 26, 2024

From clinician trust to algorithm accuracy and patient privacy, there’s significant uncertainty about AI’s potential and impact in the healthcare sector, a topic that garnered considerable attention at this year’s South by Southwest conference.

84

84

Drug Topics

JULY 26, 2023

Ycanth (cantharidin) was approved for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older as an in-office administered therapy.

FDA 98

FDA 98

Drug Topics

MARCH 27, 2023

Drug Topics® is joined by Thomas W. Taylor, the owner of Williamsburg Drug, for a conversation about starting an independent pharmacy, maintaining patient relationships, and more.

Independent Pharmacies 98

Independent Pharmacies 98

PQA

FEBRUARY 15, 2024

PQA and the Patient Advocate Foundation convened a diverse group of patients and pharmacy stakeholders in 2022 to identify and prioritize patient-centered outcomes research (PCOR) topics and evidence needed to improve social determinants of health (SDOH) screening and interventions in the pharmacy setting.

Community Pharmacies 59

Community Pharmacies 59

Pharmacy Times

NOVEMBER 3, 2022

Researcher suggests that medications for high blood pressure may be useful in treating patients with slow-onset IgA nephropathy, a topic he will present on this weekend at ASN Kidney Week in Orlando, Florida.

132

132

Drug Topics

NOVEMBER 17, 2022

Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, discusses topics to address with patients to ensure appropriate self-administration of insulin. Jennifer D.

98

98

STAT

FEBRUARY 22, 2024

Abridge sells an AI tool that rapidly transcribes and summarizes doctors’ conversations with patients in a hospital’s electronic health records software. The startup, Abridge, also has an unlikely cheerleader: Paul Ricci, the former head of Nuance, the service from Microsoft it competes with.

Hospitals 113

Hospitals 113

Hospital Pharmacy Europe

JUNE 19, 2023

Topical roflumilast is being increasingly trialled for a number of skin conditions but how effective is it, and will it take centre stage in the field of dermatology? But how effective is topical roflumilast in the management of skin diseases? Psoriasis management Topical roflumilast 0.3% foam in patients with the condition.

FDA 98

FDA Hospitals 98

Drug Topics

AUGUST 31, 2022

Drug Topics® sits down with George Euson, whose decades of experience in regulatory compliance for the pharmacy industry provide an insider's perspective on threats your business — and your patients — face today.

98

98

pharmaphorum

OCTOBER 26, 2022

Topicals — creams, ointments, foams, and lotions applied directly to the affected areas of the skin — don’t get nearly as much TV time as their systemic biologic counterparts, the self-injectables with catchy theme songs, where the smiley and sleeveless walk confidently down the street and/or swim. How to quantify severity.

Immunization 98

Immunization Adverse Reactions Insurance FDA 98

Therapeutics Education Collaboration

MARCH 15, 2024

In episode 567, Mike and James revisit the old topic of industry influence on health care providers. We go over the issues, the nuances and some of the latest evidence around the interactions, the influence, and patient perceptions.

59

59

Drug Topics

OCTOBER 27, 2023

Drug Topics sat down with Marvin Richardson, CEO of iA, a company that develops software to help patients and pharmacists, to discuss burnout in pharmacy, how the industry can improve, what will happen if it doesn’t, and how iA is working to make the job easier for pharmacists.

98

98

pharmaphorum

DECEMBER 28, 2023

In this third instalment of the five-part, festive series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Mark Andrews, investment director of life sciences funds at British Patient Capital (BPC), discussing the vitally hot topic of investment in life sciences.

63

63

Pharmacy Times

JULY 17, 2023

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

65

65

Pharmaceutical Technology

JULY 19, 2022

as a topical treatment of nonsegmental vitiligo in adults and paediatric patients aged 12 years and above. Opzelura is a topical formulation of a Janus kinase (JAK) inhibitor. With the latest development, Opzelura has became the first treatment for repigmentation in patients with vitiligo to receive FDA approval.

FDA 116

FDA Labelling 116

The Checkup by Singlecare

JANUARY 16, 2024

Triamcinolone acetonide cream is one of the most popular topical steroids prescribed to treat eczema. Triamcinolone acetonide is one of the most popular topical steroids given for atopic dermatitis, or eczema,” says George Han, MD, Ph.D., a dermatologist at Northwell Health in New Hyde Park, New York. live with this condition.

Insurance Coverage 105

Insurance Coverage FDA Dosage Insurance 105

Hospital Pharmacy Europe

JULY 27, 2023

A network meta-analysis of 221 randomised controlled trials with over 65,000 patients, has confirmed that oral isotretinoin is the most effective acne treatment. Acne can be managed with broad range of topical and oral agents including antibiotics and even aldosterone receptor antagonists such as spironolactone.

Hospitals 52

Hospitals 52

Drug Store News

DECEMBER 19, 2023

Dapsone Gel is a sulfone indicated for the topical treatment of acne vulgaris in patients aged 9 years old and older.

59

59

STAT

OCTOBER 19, 2023

Lawmakers brought up 23 different bills on the topic, many of which are drafts that haven’t been introduced. If Congress does not act before the end of the year, Medicare will cut payments to doctors in certain rural areas and laboratories that run tests used in caring for patients.

109

109

Pharmaceutical Technology

MAY 26, 2023

Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. Patients with DEB have extremely fragile skin that blisters and tears with minor trauma or friction such as scratching or rubbing.

FDA 105

FDA 105

Drug Store News

SEPTEMBER 14, 2022

Epiduo Forte is indicated for the topical treatment of acne vulgaris in adults and pediatric patients aged 12 years old and older.

97

97

PharmExec

DECEMBER 19, 2023

Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable.

FDA 52

FDA 52

indispensable health

AUGUST 14, 2023

Introduction In the fast-paced and intricate world of healthcare, seamless coordination between various departments is crucial to ensure quality patient care and effective administration. Every minute saved can be channeled into making strategic decisions, enhancing patient care, or addressing critical issues.

Hospitals 98

Hospitals Patient Care Communication 98

Board Vitals - Pharmacist

NOVEMBER 15, 2023

The PRITE covers a broad range of topics within the field of psychiatry. Administered annually, it covers a wide array of topics to ensure a well-rounded evaluation of a resident’s understanding of psychiatry. What is the PRITE ? What is the PRITE ? Let’s break down the latest PRITE blueprint : A.

98

98

BioPharm

MAY 25, 2023

FDA has approved the first topical gene therapy product for treating wounds in patients with dystrophic epidermolysis bullosa.

FDA 98

FDA 98

European Pharmaceutical Review

NOVEMBER 17, 2023

The European Commission has approved Ebglyss (lebrikizumab) for atopic dermatitis patients 12 years and older with a body weight of at least 40kg, who are candidates for systemic therapy. The Phase III clinical development programme, which involved some 1,300 patients, also evaluated the safety profile of lebrikizumab.

Hospitals 84

Hospitals 84

Hospital Pharmacy Europe

JANUARY 16, 2023

Lebrikizumab targets interleukin (IL)-13 and in combination with topical steroids appears effective in moderate to severe atopic eczema. Both emollients and topical corticosteroids (topical steroids) are used to manage mild to moderate disease whereas systemic therapy and or phototherapy is recommended for those with more severe disease.

Hospitals 52

Hospitals 52

The Checkup by Singlecare

FEBRUARY 20, 2024

Patients affected by this skin disease span all ages and genders, often having a family history of the condition and many times having an associated risk factor like obesity, smoking, and alcohol use. Vtama offers another topical treatment option to help avoid the topical corticosteroid side effect of skin atrophy or thinning.

FDA 52

FDA Immunization 52

STAT

MAY 19, 2023

The therapy, known as Vyjuvek and made by Krystal Biotech, will soon be available for patients with dystrophic epidermolysis bullosa, a genetic disease that causes painful blisters and persistent wounds. Patients with the condition live covered in bandages to try to stop new blisters from forming and to dress their wounds.

FDA 101

FDA 101

STAT

MAY 22, 2023

I once saw a patient who came to the emergency room with injuries that were clearly related to domestic violence. While facing the computer screen, the nurse asked the patient a series of sensitive questions, including one about whether she had experienced domestic violence. Read the rest…

96

96

Pharmaceutical Technology

MAY 2, 2023

Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients. Patients applied the PTX mucoadhesive gel four times a day for up to 14 days for treating current mouth ulcers.

52

52